|
C2ORF42 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.70270000216166E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.64013247427874E-12 |
| Stage1-vs-Stage2 |
3.689200E-01 |
| Stage1-vs-Stage3 |
2.077900E-02 |
| Stage1-vs-Stage4 |
4.860000E-03 |
| Stage2-vs-Stage3 |
1.786090E-02 |
| Stage2-vs-Stage4 |
6.220700E-03 |
| Stage3-vs-Stage4 |
3.120000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.04989999974536E-07 |
| Normal-vs-Asian |
1.13230003151443E-09 |
| Caucasian-vs-AfricanAmerican |
6.841200E-01 |
| Caucasian-vs-Asian |
1.278650E-01 |
| AfricanAmerican-vs-Asian |
5.341400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.42819131257966E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
9.877200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(41-60Yrs) |
7.99360577730113E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62680979798324E-12 |
| Normal-vs-Age(81-100Yrs) |
4.96439999997378E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.798800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.667000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.532400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.892200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.791000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.943800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.94130000000337E-06 |
| Classical-VS-Follicular |
1.034240E-01 |
| Classical-VS-Other |
2.833400E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
6.56889999950394E-07 |
| Tall-VS-Other |
3.516800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.705380E-01 |
| Follicular-VS-Normal |
2.78030000133711E-08 |
| Other-VS-Normal |
4.1991000000019E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.0769163338864E-14 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.22060000000446E-05 |
|
|
